Our Commitment
At APS Medical Technology, we are committed to sourcing and exporting an extensive range of premium xenograft biomaterials sourced from BSE-free countries (Australia and New Zealand, for example), including bovine and porcine pericardium, tendon, bone and other co-products. Our high-quality pericardial patches offer exceptional strength and elasticity, ideal for applications in bio-prosthetic heart valves, surgical reinforcement, and tissue regeneration, while our fresh tissues are used in a wide range of applications and can be shipped anywhere in the world using our proprietary shipping solution to suppresses bioburden for up to 14 days. We uphold rigorous quality and compliance standards (ISO 13485, ISO 22442) to ensure our products meet global regulatory requirements, and we can assist you at all stages along your own regulatory pathway.
With over 80 years of biomaterials experience across our Executive team, we believe that we are ideally positioned to provide medical device manufacturers globally with an alternative to the large, corporate suppliers currently in the market, instead offering tailored solutions to meet our clients’ existing and future requirements. Our dedication to innovation internally, and also in collaboration with leading medical institutions, enables us to deliver superior, biocompatible products that advance regenerative medicine and medical device manufacturing. If you would like to learn more about our products and services please Contact Us and we would be delighted to discuss your specific biomaterials needs in more detail.
Powered by Excellence
APS is built on a team of MedTech professionals with decades of global market leading experience with international experts across every function of its C-suite.
Professor Ian Meredith director of Monash heart for 12 years and Chief Medical Officer Boston Scientific 2017 to 2023.
The measure of any successful business is the quality of its people. APS has assembled a team with exceptional knowledge and standalone experience across all facets that will create sustainable value to shareholders and facilitate the secure growth of this market leading MedTech enterprise.
Professor Ian Meredith,
AM Chief Medical Officer
Australian Pericardium Solutions
